Opko Health, Inc. Presents 4Kscore™ Test Clinical Study At The American Urological Association Plenary Session

Published: May 20, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OPKO Health, Inc. (NYSE:OPK) announced the results of the data from its blinded, prospective clinical study of the 4Kscore Test at 26 leading Urology centers across the United States. The results demonstrated the 4Kscore Test is the most accurate, personalized predictor for risk of high-grade cancer. The data were presented by Dr. Daniel W. Lin, Professor and Chief of Urologic Oncology at the University of Washington, as a Late-Breaking abstract at the Plenary I Session on Sunday May 18, 2014 at the American Urological Association (AUA) annual meeting in Orlando, FL.

Help employers find you! Check out all the jobs and post your resume.

Back to news